% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rejeski:302989,
      author       = {K. Rejeski$^*$ and J. A. Hill and S. Dahiya and M. D. Jain},
      title        = {{N}oncanonical and mortality-defining toxicities of {CAR}
                      {T} cell therapy.},
      journal      = {Nature medicine},
      volume       = {31},
      number       = {7},
      issn         = {1078-8956},
      address      = {[New York, NY]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-01436},
      pages        = {2132-2146},
      year         = {2025},
      note         = {2025 Jul;31(7):2132-2146},
      abstract     = {Chimeric antigen receptor (CAR) T cell therapy is
                      associated with a unique spectrum of toxicities that drive
                      morbidity, mortality and patient quality of life. Previous
                      efforts yielded consensus grading systems for the
                      prototypical immunotoxicities-namely, cytokine-release
                      syndrome (CRS) and immune effector cell-associated
                      neurotoxicity syndrome (ICANS). These grading systems set
                      the stage for severity-based and standardized treatment
                      protocols that have contributed to a reduction in the acute
                      toxicity burden of CAR T cell therapy and have enabled
                      outpatient administration. However, understanding of CAR T
                      cell therapy has since grown to encompass new targets, new
                      diseases and broader patient populations-including long-term
                      survivors. As side effects are better defined and novel
                      toxicities emerge, there is a need to understand their
                      mechanisms and standardize reporting to improve clinical
                      management. Here we review the current state of knowledge
                      for mortality-defining and rare toxicities of CAR T cell
                      therapies, beyond CRS and ICANS. We discuss mechanisms,
                      including on-target injury, cytokine-associated inflammation
                      and dysregulated recovery, and how these mechanisms affect
                      the timing and management of toxicities. Finally, we define
                      key unmet needs and delineate future priorities and research
                      directions.},
      subtyp        = {Review Article},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40670774},
      doi          = {10.1038/s41591-025-03813-5},
      url          = {https://inrepo02.dkfz.de/record/302989},
}